Monte Rosa Therapeutics, Inc. GLUE R2KR3KPHARMA
Company Overview
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.08.
Recent Developments
- Dec 2025 Revenue of $123.67M (+63.5% YoY); net profit $-38.63M.
- Trailing 12 Months Year-on-year growth — revenue -61.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -61.30% |
Stock Price Performance
| 1 Year: | +144.14% |
| 6 Months: | -45.22% |
| 3 Months: | -51.95% |
| 1 Month: | -7.51% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 57.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GLUE Monte Rosa Therapeutics, Inc. R2KR3KPHARMA | 10.84 | -6.19 | $924.80M | 0.00% | -14.10% | -42.66% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.06M | 4.70M | 9.22M | 84.93M | 23.19M | 12.77M | 4.21M | 8.97M |
| Operating Income | - | -5.40M | -6.39M | -11.50M | -18.12M | -19.87M | -24.30M | -27.23M | -28.36M | -34.26M | -37.22M | -36.97M | -34.95M | -32.64M | -26.53M | 44.04M | -15.55M | -32.98M | -50.03M | -49.13M |
| Net Income | -4.30M | -5.36M | -6.56M | -12.28M | -18.41M | -19.84M | -23.93M | -26.47M | -27.32M | -32.04M | -35.18M | -34.88M | -31.97M | -30.31M | -23.86M | 46.88M | -12.29M | -27.08M | -44.50M | -43.40M |
| R&D Expense | - | 4.86M | 5.47M | 9.27M | 14.64M | 15.12M | 17.91M | 20.94M | 21.34M | 26.75M | 29.08M | 28.31M | 27.03M | 28.05M | 27.62M | 32.19M | 30.65M | 36.68M | 44.07M | 47.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 75.62M | 123.67M |
| Operating Income | -28.01M | -72.88M | -112.38M | -143.31M | -81.11M | -54.21M |
| Net Income | -35.88M | -73.96M | -108.50M | -135.35M | -72.70M | -38.63M |
| R&D Expense | 24.00M | 57.16M | 85.06M | 111.27M | 121.56M | 141.50M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | 49.38M | - | 342.39M | 303.75M | 438.73M | 448.66M |
| Current Assets | - | - | 275.89M | 236.21M | 377.44M | 393.19M |
| Cash & Equivalents | 41.70M | - | 54.91M | 128.10M | 224.25M | 129.88M |
| Inventory | - | - | - | - | - | - |
| Receivables | - | - | 7.66M | 505.00K | 173.00K | 11.60M |
| Total Liabilities | 30.34M | - | 70.98M | 124.50M | 215.80M | 215.60M |
| Current Liabilities | 29.27M | - | 25.57M | 46.59M | 156.95M | 64.21M |
| Long Term Debt | - | - | - | - | - | - |
| Total Debt | - | - | 47.00M | 46.04M | 42.72M | 39.19M |
| Total Equity | -48.73M | - | 271.41M | 179.25M | 222.94M | 233.06M |
| Shares Outstanding | - | - | 49.45M | 50.14M | 61.51M | 65.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.05M | - | -92.47M | -43.80M | 42.00M | -22.80M |
| Investing Cash Flow | -3.39M | - | -219.22M | 88.80M | -44.45M | -101.83M |
| Financing Cash Flow | 60.06M | - | 20.47M | 27.49M | 98.89M | 30.35M |
| Capital Expenditure | -3.39M | - | -12.91M | -19.04M | -3.99M | -4.70M |
| Free Cash Flow | -26.44M | - | -105.38M | -62.84M | 38.01M | -27.50M |
| Net Change in Cash | - | - | -291.22M | 72.49M | 96.44M | -94.28M |
| Dividends Paid | - | 0 | 0 | 0 | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -107.3% | -43.8% |
| Net Margin % | - | - | - | - | -96.1% | -31.2% |
| ROE % | 73.6% | - | -40.0% | -75.5% | -32.6% | -16.6% |
| ROCE % | -139.3% | - | -35.5% | -55.7% | -28.8% | -14.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Price (T.Rowe) Associates Inc | 10.39% | 8.86M | $91.27M |
| 2 | NEA Management Company, LLC | 9.02% | 7.69M | $79.23M |
| 3 | Blackrock Inc. | 8.02% | 6.84M | $70.48M |
| 4 | TCG Crossover Management, LLC | 5.42% | 4.62M | $47.61M |
| 5 | Vestal Point Capital, LP | 5.39% | 4.60M | $47.38M |
| 6 | BVF Inc. | 5.23% | 4.46M | $45.95M |
| 7 | Baker Bros. Advisors, LP | 5.09% | 4.35M | $44.76M |
| 8 | State Street Corporation | 4.37% | 3.73M | $38.43M |
| 9 | Montanova Capital LLC | 4.16% | 3.55M | $36.56M |
| 10 | Vanguard Capital Management LLC | 4.00% | 3.41M | $35.15M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GLUE
Monte Rosa Therapeutics Stock Price Forecast. Should You Buy GLUE? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFBmd3hNZFRydVpIcy1kVl96dXdRV2ZBal9hdmZYdzhPaFo5el9MSU1hSkttcTRZajBmSldDZEVJYkJkamd6NmJPRQ?oc=5" target="_blank">Monte Rosa Therapeutics Stock Price Forecast. Should You Buy GLUE?</a…
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Jumps 8% - Here's What Happened - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPbmdDRWpacnZRdTFwSU1qZVd6Ymo0TllSdjUyWUhLZkNXdy1QczhpbkFPYzJVWlNGYWxkUGxtcGdYQjMwcmpZYlp4Qi1ZUVhhalkyOUVMdVBOcnpTRXlsRWs0REtnSlJjTDlmMDI0cC10QkJlcERKcmRlTU1VcGJoaFdROFREX1phSmQ1bk…
Monte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOT1RiZ2tuLXVDdTZ2ODhpcWc3R3owenN2dVZVc1pveWJjNXY0SVBsRXpBWTRLbFBROWpEbzV0WVZhTTJhRWxaLTF6aXN6VEoxb2RYVUVRMXR3Vjc3ZlZGczR3MkM1S1E4MHFaMnAyT01mZktENDFTaEI5MHYtVVVnbFFTYTV4SW9LYnhLUD…
GLUE Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5zWnRYSVF5T3hJYnRHcU9GejNYM295UUU2Z1p4REJFUENRMGNBaUFicTBRQTFIQXgtZjlfT1dzcXlHQ3RDYVdzUzg0alYwRWRnUm9yeEN3d0FiZXBCeTFpcjZvNmk1ZmdHZmJMVU9Jd3p5b256R1UxYXRB?oc=5" target="_blank">GLU…
GLUE Stock Slips Pre-Market After Pricing $300 Million Public Offer At Discount - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxNaUllb3lVNEdlOWdvM0ZWd2I4QWpPclZMa0pKWm1JVjZvNWg1MWVrWlZhZGRxTldZMUNQSmpoNGVLNTVUZHRBYWdTaWFUZHQ5ZlQzaUpkMTh3LVd5VVcxcTlZRWR5bmxKY240ZGV6T1oxWTVCdFRCMm1LNVYtdzJvdmdDU2lJcTRVN2JwZn…
Apple's new $79 iPhone Duo case requires actual glue to stay on your phone - PhoneArena
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQNGhySXdlQ2RKVnVvSFFFdU4zMTFfMXJTamNyLTh4OWJ6S2pfZW9KelZDZjFZZVAwUV9maFpkSDRIaFdqM2poeVFTcnpMUHlZRWVnQUd2SFFxQWxQcFl3MUR2a191Nzg4a25CVlZiMUZlMmFFWjRtTGhTcG1YNW9WbThQa1BraWN1b1VxZD…
GLUE — Frequently Asked Questions
What is the current share price of Monte Rosa Therapeutics, Inc. (GLUE)?
As of 2026-10-23 16:27 PDT, Monte Rosa Therapeutics, Inc. (GLUE) trades at $10.84 on NasdaqGS. Its 52-week range is $4.35 to $25.31.
What is the market capitalisation of GLUE?
Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalisation of $924.80M on NasdaqGS.
What is the P/E ratio of GLUE?
GLUE trades at a trailing price-to-earnings (P/E) ratio of -6.19. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.12.
What is the return on equity (ROE) of GLUE?
GLUE has a return on equity (ROE) of -42.66%. Its return on capital employed (ROCE) is -14.10%.
Is GLUE a good stock to buy?
This page provides a data-driven analysis of Monte Rosa Therapeutics, Inc. (GLUE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.